Table 3.
Comparison of outcomes reported for metastatic melanoma cohorts with an initial CR to BRAFi ± MEKi therapy.
| Reports Analzying Outcomes after TT Cessation | Number of Patients (CR) | Median Duration of TT Treatment (Months) | Discontinuation due to Toxicity | Median Follow-up after Discontinuation (Months) | Tumor Progression (%) | Median PFS upon TT Cessation | Response to TT Rechallange |
|---|---|---|---|---|---|---|---|
| Warburton [31] | 13 | 39 | 0% | 19 | 0% | 5 | 100% |
| Wyluda [34] | 3 | 12 | 100% | 15 | 0% | NA | NA |
| Desvignes [32] | 6 | 6 | 100% | 15 | 100% | 4 | 17% |
| Vanhaecke [33] | 16 | 21 | 63% | 12 | 53% | 2.5 | 63% |
| Tolk [35] | 12 | 13 | 54% | 17 | 46% | 3 | 50% |
| Carlino [22] | 12 | NA | 100% | 16 | 50% | 6.6 | 33% |
| Stege | 37 | 16 | 16% | 19 | 69% | 1 | 60% |